Objectives: Suprachoroidal injection of triamcinolone acetonide is the first Food and Drug Administration-approved treatment for macular edema associated with uveitis. A cost-effectiveness analysis was performed comparing this treatment with best supportive care (BSC) for the management of this indication from US Medicare and commercial payer perspectives.
Methods: A patient-level simulation was developed per the patient characteristics and changes in best-corrected visual acuity letter scores observed in a phase III study of triamcinolone acetonide (PEACHTREE). The wholesale acquisition cost of triamcinolone acetonide was $1650/injection; suprachoroidal injection cost was assumed at $200/injection. Healthcare costs were informed by a US claims-based analysis. Mortality risk associated with severe vision loss and blindness was modeled by applying a hazard ratio to all-cause mortality rates of the US general population. Health-related quality of life weights, obtained from a regression model fitted to the Visual Function Questionnaire-25 data from PEACHTREE, were applied based on the best-corrected visual acuity scores of both eyes. Costs (2020 US dollar) and benefits were discounted at 3% annually. Incremental cost-effectiveness ratios were estimated over a 10-year horizon.
Results: In the base-case, the incremental cost-effectiveness ratio comparing triamcinolone acetonide with BSC was $28 479 per quality-adjusted life-year gained. The wholesale acquisition cost for triamcinolone acetonide for suprachoroidal use was ∼68%, ∼56%, and ∼27% below the willingness-to-pay thresholds of $150 000, $100 000, and $50 000 per quality-adjusted life-year gained, respectively. Results were robust in sensitivity and scenario analyses.
Conclusions: Triamcinolone acetonide for suprachoroidal use is cost-effective compared with BSC for patients with macular edema associated with uveitis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jval.2022.07.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The efficacy of fractional CO laser with or without triamcinolone acetonide or 5-fluorouracil in the treatment of early postburn hypertrophic scars.
Lasers Med Sci
January 2025
Plastic Surgery Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Hypertrophic scars (HTSs) are the result of an abnormal healing process resulting from burns and other severe traumas. The symptoms of that condition include skin irritation, discomfort, and itching. This study aimed to assess the efficacy of fractional carbon dioxide (CO) laser therapy alone or with triamcinolone or 5-fluorouracil (FU) in the treatment of early post-burn hypertrophic scars (HTSs) that develop during the first 6 months after the injury.
View Article and Find Full Text PDFCoats-Like reaction post-vitreoretinal surgery for PDR managed with laser photocoagulation and adjunctive intravitreal steroids- a case report.
BMC Ophthalmol
January 2025
Dept. of Retina and Vitreous, Narayana Nethralaya, #121/C, 1st R Block, Chord Road, Rajaji Nagar, Bengaluru, 560010, India.
Purpose: To report a rare case of a Coats-like response developing after vitreoretinal surgery for proliferative diabetic retinopathy (PDR) and its successful management with retinal laser photocoagulation and adjunctive intravitreal steroids.
Case Description: A 52-year-old woman with a five-year history of type 2 diabetes mellitus and hypertension presented with decreased vision in the left eye (counting fingers at 1 m). Examination revealed high-risk PDR in both eyes, with a subtotal macula-off combined retinal detachment in the left eye.
Effectiveness and cytokine profile of combined anti-vascular endothelial growth factor and corticosteroid therapy for chronic retinal vein occlusion.
Graefes Arch Clin Exp Ophthalmol
January 2025
Department of Ophthalmology and Micro-Technology, Yokohama City University, 4-57 Urafunecho, Minami-ku, Yokohama, 232-0024, Kanagawa, Japan.
Purpose: To investigate whether sub-Tenon injection of triamcinolone acetonide (STTA) combined with anti-vascular endothelial growth factor (VEGF) prolongs the recurrence intervals of macular edema (ME) for chronic retinal vein occlusion (RVO) and to investigate the differences in intraocular inflammatory cytokines between good responders (GRs) and non-responders (NRs).
Methods: This retrospective, observational study involved 42 eyes of 42 patients with ME due to chronic RVO who had received only anti-VEGF for ≥ 1 year and were transitioned to combination therapy. GRs were defined as patients whose recurrence intervals were prolonged by ≥ 2 weeks compared with patients receiving anti-VEGF alone.
The management of locally advanced esophageal cancer typically involves esophagectomy; however, postoperative complications, particularly anastomotic stricture, remain prevalent. Anastomotic stricture can severely compromise patients' quality of life by leading to difficulties in food intake. Although endoscopic balloon dilation has become a standard treatment for gastrointestinal strictures, its efficacy is often limited due to the risk of perforation and the potential for recurrent stricture, necessitating multiple interventions.
View Article and Find Full Text PDFAmniotic Tissue Injections Are an Effective Alternative to Corticosteroid Injections for Pain Relief and Function in Patients With Severe Knee Osteoarthritis: A Double-Blind, Randomized, Prospective Study.
J Am Acad Orthop Surg Glob Res Rev
January 2025
From the Steadman Hawkins Clinic of the Carolinas, Prisma Health-Upstate, Greenville, SC (Dr. Pill, Dr. Ahearn, Dr. Siffri, Dr. Burnikel, Dr. Cassas, Dr. Wyland, and Dr. Kissenberth); the Mayo Clinic Arizona, Scottsdale, AZ (Dr. Tokish); the Department of Orthopaedics, Duke University, Durham NC (Dr. Cook); the Laboratory of Orthopaedic Tissue Regeneration & Orthobiologics, Department of Bioengineering, Clemson University, Clemson, SC (Dr. Mercuri, Mr. Sawvell, and Mr. Wright); the Frank H. Stelling and C. Dayton Riddle Orthopaedic Education and Research Laboratory, Clemson University Biomedical Engineering Innovation Campus, Greenville, SC (Dr. Mercuri, Mr. Sawvell, and Mr. Wright); and the Hawkins Foundation, Greenville, SC (Dr. Hutchinson, Dr. Bynarowicz, and Dr. Adams).
Introduction: The use of corticosteroid injections for short-term pain relief for knee osteoarthritis can have deleterious adverse effects. Amniotic tissue has shown promise in vitro; therefore, this study compared a morcellized injectable amniotic tissue allograft to corticosteroid injection.
Methods: Eighty-one patients with symptomatic severe knee osteoarthritis (Kellgren-Lawrence grade 3 to 4) were prospectively randomized to either a double-blinded single injection of BioDRestore (Integra LifeSciences; n = 39) or triamcinolone acetonide (n = 42).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!